Pipeline
![](https://www.centurytx.com/wp-content/uploads/2021/11/pipeline-image.png)
![](https://www.centurytx.com/wp-content/uploads/2021/11/century_desktop_3_03.jpg)
![](https://www.centurytx.com/wp-content/uploads/2021/11/century_mobile_0_04.jpg)
Pipeline Overview
We are assembling a robust portfolio of allogeneic iPSC derived NK, γδ and αβ T cell therapy product candidates for cancer and autoimmune and inflammatory diseases. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses. Enhancements in this platform have led to the generation of cells with pan-resistance to host T cell, NK, and antibody (ADCC/ADCP/Complement) mediated rejection to potentially optimize and increase the probability of success of our programs across hematology, oncology, and autoimmune and inflammatory diseases.
![](https://www.centurytx.com/wp-content/uploads/pipeline_4-9-24.png)